Sign Up to like & get recommendations! 1
Published in 2022 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2022.31930
Abstract: Key Points Question How commonly are patient-reported outcomes (PROs) used and how well are they reported in clinical trials of palliative radiotherapy? Findings In this systematic review that included 225 published clinical trials representing 24 281… read more here.
Sign Up to like & get recommendations! 0
Published in 2020 at "JAMA pediatrics"
DOI: 10.1001/jamapediatrics.2020.2987
Abstract: This cross-sectional study evaluates whether the Parent-Reported Outcomes of Symptoms system identifies more symptoms than clinicians do among children with severe neurological impairment. read more here.
Sign Up to like & get recommendations! 1
Published in 2022 at "Autism Research"
DOI: 10.1002/aur.2833
Abstract: The objectives of this study were to (1) demonstrate the application of percentiles to advance the interpretation of patient‐reported outcomes and (2) establish autism‐specific percentiles for four Patient‐Reported Outcomes Measurement Information System (PROMIS) measures. PROMIS… read more here.
Sign Up to like & get recommendations! 0
Published in 2021 at "Cancer Medicine"
DOI: 10.1002/cam4.3826
Abstract: Missing patient reported outcomes data threaten the validity of PRO‐specific findings and conclusions from randomized controlled trials by introducing bias due to data missing not at random. Clinical Research Associates are a largely unexplored source… read more here.
Sign Up to like & get recommendations! 2
Published in 2022 at "Cancer Medicine"
DOI: 10.1002/cam4.4692
Abstract: We investigated the prognostic value of pretreatment patient‐reported outcomes (PROs) in patients with diffuse large B‐cell lymphoma (DLBCL) receiving obinutuzumab/rituximab plus chemotherapy in the GOYA phase III study. read more here.
Sign Up to like & get recommendations! 1
Published in 2022 at "Cancer"
DOI: 10.1002/cncr.34420
Abstract: Systemic mastocytosis (SM) is a rare clonal neoplasm driven by KIT D816V and other mutations. Data were collected from the patient perspective on disease burden and included an SM‐specific symptom assessment tool. read more here.
Sign Up to like & get recommendations! 0
Published in 2018 at "Hepatology"
DOI: 10.1002/hep.30356
Abstract: 443 placebo is observed in patient-reported outcomes or subjective measures; the effect of placebo on objective biomarkers or hard outcomes such as mortality are likely minimal.(2) Hence, in this study, when evaluating mortality as primary… read more here.
Sign Up to like & get recommendations! 2
Published in 2023 at "Journal of inherited metabolic disease"
DOI: 10.1002/jimd.12622
Abstract: INTRODUCTION Patient reported outcomes (PROs) are generally defined as "any report of the status of a patient's health condition that comes directly from the patient, without interpretation of the patient's response by a clinician or… read more here.
Sign Up to like & get recommendations! 0
Published in 2017 at "Journal of Orthopaedic Research"
DOI: 10.1002/jor.23604
Abstract: Patient reported outcome measures (PROMs) are key tools when performing clinical research and PROM data are increasingly used to inform clinical decision‐making, patient‐centered care, health policy and more recently, reimbursement decisions. PROMs must possess particular… read more here.
Sign Up to like & get recommendations! 0
Published in 2021 at "Journal of Surgical Oncology"
DOI: 10.1002/jso.26690
Abstract: This review explores how human papillomavirus‐related oropharyngeal cancer affects health‐related quality of life (HR‐QoL) and the role patient‐reported outcomes (PROs) can play in optimizing treatment. PRO measures (PROMs) are comprehensive, subjective assessments of patients’ day‐to‐day… read more here.
Sign Up to like & get recommendations! 1
Published in 2022 at "Journal of Surgical Oncology"
DOI: 10.1002/jso.27012
Abstract: Numerous experimental and targeted therapies are under investigation for patients with cholangiocarcinoma (CCA). Objective health‐related quality of life (HRQoL) data for patients receiving these therapies are limited. read more here.